The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels
Open accessAbstract
BACKGROUND: We investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos. METHODS: A group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay. RESULTS: There were no significant differences in mean (+/-SE) serum osteopontin levels between age-matched subjects with exposure to asbestos and subjects without exposure to asbestos (30+/-3 ng per milliliter and 20+/-4 ng per milliliter, respectively; P=0.06). In the group with exposure to asbestos, elevated serum osteopontin levels were associated with pulmonary plaques and fibrosis (56+/-13 ng per milliliter) but not with normal radiographic findings (21+/-5 ng per milliliter), plaques alone (23+/-3 ng per milliliter), or fibrosis alone (32+/-7 ng per milliliter) (P=0.004). Serum osteopontin levels were significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos (133+/-10 ng per milliliter vs. 30+/-3 ng per milliliter, P<0.001). Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma. An analysis of serum osteopontin levels comparing the receiver-operating-characteristic curve in the group exposed to asbestos with that of the group with mesothelioma had a sensitivity of 77.6 percent and a specificity of 85.5 percent at a cutoff value of 48.3 ng of osteopontin per milliliter. Subgroup analysis comparing patients with stage I mesothelioma with subjects with exposure to asbestos revealed a sensitivity of 84.6 percent and a specificity of 88.4 percent at a cutoff value of 62.4 ng of osteopontin per milliliter. CONCLUSIONS: Serum osteopontin levels can be used to distinguish persons with exposure to asbestos who do not have cancer from those with exposure to asbestos who have pleural mesothelioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
Zweig, M. H., & Campbell, G. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.561 · Cited by 6,569
Basic principles of ROC analysis
Metz, C. E. (1978) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(78)80014-2 · Cited by 6,026
Mesothelin-family proteins and diagnosis of mesothelioma
Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E., & Hellstrom, I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14794-0 · Cited by 534
Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
Kim, J.-H. (2002) · JAMA · doi:10.1001/jama.287.13.1671 · Cited by 480
The role of Osteopontin in tumor metastasis
Wai, P. Y., & Kuo, P. C. (2004) · Journal of Surgical Research · doi:10.1016/j.jss.2004.03.028 · Cited by 365
Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A. F., & Yeatman, T. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1405-2 · Cited by 341
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
Rusch, V. W., & Venkatraman, E. S. (1999) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(99)01038-3 · Cited by 250
The importance of surgical staging in the treatment of malignant pleural mesothelioma
Rusch, V. W., & Venkatraman, E. (1996) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(96)70342-2 · Cited by 205
Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma
Koopmann, J., Fedarko, N. S., Jain, A., Maitra, A., Iacobuzio-Donahue, C., Rahman, A., Hruban, R. H., Yeo, C. J., & Goggins, M. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.487.13.3 · Cited by 195
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma
McIntosh, M. W., Drescher, C., Karlan, B., Scholler, N., Urban, N., Hellstrom, K. E., & Hellstrom, I. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.039 · Cited by 193
Rusch, V. W. (1996) · Lung Cancer · doi:10.1016/0169-5002(95)00508-0 · Cited by 179
Roggli, V. L., Sharma, A., Butnor, K. J., Sporn, T., & Vollmer, R. T. (2002) · Ultrastructural Pathology · doi:10.1080/01913120252959227 · Cited by 176
Changing trends in US mesothelioma incidence
Weill, H., Hughes, J., & Churg, A. (2004) · Occupational and Environmental Medicine · doi:10.1136/oem.2003.010165 · Cited by 140
Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma
Pass, H. I., Liu, Z., Wali, A., Bueno, R., Land, S. J., Lott, D., Siddiq, F., Lonardo, F., Carbone, M., & Drăghici, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0607-3 · Cited by 123
Self-citationOsteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
Schorge, J. O., Drake, R. D., Lee, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0365 · Cited by 101
Concentration of Hyaluronic Acid in Pleural Fluid as a Diagnostic Aid for Malignant Mesothelioma
Pettersson, T., Fröseth, B., Riska, H., et al. (1988) · CHEST Journal · doi:10.1378/chest.94.5.1037 · Cited by 90
Predictors of Lung Cancer among Asbestos-exposed Men in the -Carotene and Retinol Efficacy Trial
Cullen, M. R. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi034 · Cited by 79
mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats
Sandhu, H., Dehnen, W., Roller, M., Abel, J., & Unfried, K. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.1023 · Cited by 66
Integration of Multimodality Approaches in the Management of Malignant Pleural Mesothelioma
Martino, D., & Pass, H. I. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.008 · Cited by 43
Self-citationAmberson, J. B., Vaughan, E. D., Gray, G. F., & Naus, G. J. (1987) · Cancer · doi:10.1002/1097-0142(19870615)59:12<2104::aid-cncr2820591224>3.0.co;2-i · Cited by 41
Martinetti, A., Bajetta, E., Ferrari, L., Zilembo, N., Seregni, E. C., Vecchio, M. D., Longarini, R., Torre, I. L., Toffolatti, L., Paleari, D., et al. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00775 · Cited by 32
Denhardt, D. T. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23708.x · Cited by 16
Cited by
Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., Hennequin, C., Hillerdal, G., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00063109 · Cited by 638
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., Flores, R., Friedberg, J. S., Pisters, K., Monberg, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.3943 · Cited by 467
Self-citationMalignant mesothelioma: Facts, Myths, and Hypotheses
Carbone, M., Ly, B. H., Dodson, R. F., Pagano, I., Morris, P. T., Dogan, U. A., Gazdar, A. F., Pass, H. I., & Yang, H. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22724 · Cited by 376
Self-citationAlonso, S. R., Tracey, L., Ortiz, P., Pérez-Gómez, B., Palacios, J., Pollán, M., Linares, J., Serrano, S., Sáez-Castillo, A. I., Sánchez, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3481 · Cited by 326
Metadata
- Authors
- Pass, H. I., Lott, D., Lonardo, F., Harbut, M., Liu, Z., Tang, N., Carbone, M., Webb, C., & Wali, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-10-13
- Volume
- 353
- Issue
- 15
- Pages
- 1564-1573
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4252826935
- Cited by
- 357
- References
- 23
- FWCI
- 20.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.